To the Editor:
In compliance with the Journal's editorial rules regarding disclosure of affiliations and according to my understanding of those rules, I provided a single institutional affiliation when I submitted a letter to the editor concerning hormonal treatment of prostate cancer (March 11 issue). (1) At the request of the Editors after the submission of my letter, I am providing the following information: in addition to being clinical professor of medicine (part-time) at Harvard Medical School and the Beth Israel Deaconess Medical Center, I am also chief medical officer of Praecis Pharmaceuticals, a company involved in the development of a gonadotropin-releasing hormone antagonist.
Marc B. Garnick, M.D.
Beth Israel Deaconess Medical Center
Boston, MA 02215
We regret that because of an editorial error, the disclosure statement sent to us by Dr. Mario Eisenberger was omitted from the published article "Bilateral Orchiectomy with or without Flutamide for Metastatic Prostate Cancer" (1998;339:1036-42). Dr. Eisenberger provided the following information: "Mario Eisenberger and E. David Crawford have received educational grants from Schering-Plough, or serve as scientific advisors to the company, or both. Schering-Plough donated the flutamide and placebo used in this study. Schering-Plough also provided a grant to support data management for this trial, but all data analyses were carried out at the statistical center of the Southwest Oncology Group."